JP2020527138A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527138A5
JP2020527138A5 JP2020501125A JP2020501125A JP2020527138A5 JP 2020527138 A5 JP2020527138 A5 JP 2020527138A5 JP 2020501125 A JP2020501125 A JP 2020501125A JP 2020501125 A JP2020501125 A JP 2020501125A JP 2020527138 A5 JP2020527138 A5 JP 2020527138A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020501125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527138A (ja
JP7224331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/041796 external-priority patent/WO2019014434A1/en
Publication of JP2020527138A publication Critical patent/JP2020527138A/ja
Publication of JP2020527138A5 publication Critical patent/JP2020527138A5/ja
Application granted granted Critical
Publication of JP7224331B2 publication Critical patent/JP7224331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020501125A 2017-07-12 2018-07-12 脂肪毒性損傷の低減のための化合物 Active JP7224331B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531454P 2017-07-12 2017-07-12
US62/531,454 2017-07-12
PCT/US2018/041796 WO2019014434A1 (en) 2017-07-12 2018-07-12 COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS

Publications (3)

Publication Number Publication Date
JP2020527138A JP2020527138A (ja) 2020-09-03
JP2020527138A5 true JP2020527138A5 (enExample) 2021-08-12
JP7224331B2 JP7224331B2 (ja) 2023-02-17

Family

ID=65002124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501125A Active JP7224331B2 (ja) 2017-07-12 2018-07-12 脂肪毒性損傷の低減のための化合物

Country Status (13)

Country Link
US (5) US11339126B2 (enExample)
EP (2) EP4218753B1 (enExample)
JP (1) JP7224331B2 (enExample)
KR (1) KR102679975B1 (enExample)
CN (1) CN111343999B (enExample)
AU (2) AU2018300985B2 (enExample)
BR (1) BR112020000635B1 (enExample)
CA (1) CA3069526A1 (enExample)
ES (1) ES2934883T3 (enExample)
IL (1) IL271884B2 (enExample)
PL (1) PL3651784T3 (enExample)
SG (1) SG11202000239XA (enExample)
WO (1) WO2019014434A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218753B1 (en) 2017-07-12 2025-12-03 Mayo Foundation for Medical Education and Research Novel lipase inhibitor and uses thereof
JP2024517699A (ja) * 2021-04-23 2024-04-23 パナフィナ,インコーポレイテッド リプスタチン誘導体を合成する方法
CN114560887B (zh) * 2022-02-15 2024-01-26 安徽美致诚药业有限公司 一种制备奥利司他的中间体的制备方法
CN119031909A (zh) * 2022-03-31 2024-11-26 梅约医学教育与研究基金会 用于治疗胰腺疾病和病症的方法和材料

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxetanones a process for their manufacture and pharmaceutical compositions containing them
FR2754827B1 (fr) 1996-10-17 1998-12-24 Biocem Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations
FR2758143B1 (fr) 1997-01-07 1999-02-19 Laphal Laboratoire De Pharmaco Inhibiteurs specifiques de la lipase pancreatique et leurs applications
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040018197A1 (en) 2002-04-26 2004-01-29 Promega Corporation Treatment for weight loss
DE102004009076A1 (de) 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1803714A1 (en) 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
EP2212305A4 (en) 2007-10-31 2011-10-26 Burnham Inst Medical Research BETA-lactone
US9023887B2 (en) 2011-04-15 2015-05-05 University of Pittsburgh—of the Commonwealth System of Higher Education Lipase inhibitors for the treatment of pancreatitis and organ failure
US20150099800A1 (en) 2012-05-24 2015-04-09 Northeastern University Novel lipase inhibitors, reporter substrates and uses thereof
WO2016002541A1 (ja) 2014-06-30 2016-01-07 日立工機株式会社 電動工具
EP3237011B1 (en) 2014-12-22 2021-11-10 Université Libre de Bruxelles Composition comprising vancomycin and orlistat
US20180319894A1 (en) 2015-11-03 2018-11-08 Mayo Foundation For Medical Education And Research Using colipase inhibitors to treat pancreatitis
EP4218753B1 (en) 2017-07-12 2025-12-03 Mayo Foundation for Medical Education and Research Novel lipase inhibitor and uses thereof

Similar Documents

Publication Publication Date Title
JP2020527138A5 (enExample)
JP2018518537A5 (enExample)
JP2019516739A5 (enExample)
JP2016515561A5 (enExample)
JP2014508748A5 (enExample)
JP2019529541A5 (enExample)
JP2019519533A5 (enExample)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
CN111683928A (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
JP2016516074A5 (enExample)
JP2018505882A5 (enExample)
JP2017508817A5 (enExample)
JP2019510079A5 (enExample)
JP2013500977A5 (enExample)
CN115315423A (zh) 取代芳基类化合物
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2018537513A5 (enExample)
JP2016503058A5 (enExample)
JP2017505809A5 (enExample)
JP2017518982A5 (enExample)
JP2016537338A5 (enExample)
JP2016531885A5 (enExample)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
JP2016515550A5 (enExample)
JP2014148552A5 (enExample)